Immunic, Inc.
NASDAQ:IMUX
1.18 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immunic, Inc. |
Symbool | IMUX |
Munteenheid | USD |
Prijs | 1.18 |
Beurswaarde | 106,293,220 |
Dividendpercentage | 0% |
52-weken bereik | 0.945 - 2.11 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Daniel Vitt Ph.D. |
Website | https://www.immunic-therapeutics.com |
An error occurred while fetching data.
Over Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)